Phase I and Pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in Patients with advanced solid tumors

Clinical Cancer Research

Volumn 15, Issue 1, 2009, Pages 374-381

  Zhu, Andrew X ^a   Ready, Neal ^b   Clark, Jeffrey W ^a   Safran, Howard ^b   Amato, Antonino ^c   Salem, Nadia ^c   Pace, Silvia ^d   He, Xiaoying ^a   Zvereva, Nela ^a   Lynch, Thomas J ^a   Ryan, David P ^a   Supko, Jeffrey G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c Sigma Tau Research Inc   (United States)

^d Sigma Tau SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; GIMATECAN; LACTONE; NARCOTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; CANCER PATIENT; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; DEHYDRATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSE ESCALATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FUNCTIONAL STATUS; HEMATOLOGICAL PARAMETERS; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; KIDNEY FUNCTION; LIVER FUNCTION; LIVER TOXICITY; LUNG CANCER; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; PANCREAS CANCER; PAROTID GLAND CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTHROMBIN TIME; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADULT; AGED; CAMPTOTHECIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS;

EID: 58849111389     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1024     Document Type: Article

References (35)

1. Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 2002:8:641 -61.
2. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997:15: 2183-93.
3. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999:17:658-67.
4. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343: 905-14.
5. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998:352:1413-8.
6. Rougier P.Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-12.
7. Dallavalle S, Ferrari A, Biasotti B, et al. Novel 7-oxy- iminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity. J Med Chem 2001;44:3264-74.
8. Pratesi G, Beretta GL, Zunino F. Gimatecan, a novel camptothecin with a promising preclinical profile. Anticancer Drugs 2004;15:545-52.
9. Pratesi G, De Cesare M, Carenini N, et al. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts. Clin Cancer Res 2002;8:3904-9.
10. De Cesare M, Pratesi G.Veneroni S, Bergottini R, Zunino F. Efficacy of the novel camptothecin gimatecan against orthotopic and metastatic human tumor xenograft models. Clin Cancer Res 2004;10:7357-64.
11. De Cesare M, Pratesi G, Perego P, et al. Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin. Cancer Res 2001;61:7189-95.
12. Perego P, De Cesare M, De Isabella P, et al. A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line. Cancer Res 2001:61:6034-7.
13. Gerrits CJ, de Jonge MJ, Schellens JH, Stoter G, Verweij J. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br J Cancer1997;76:952-62.
14. Petrangolini G, Pratesi G, De Cesare M, et al. Anti- angiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts. Mol Cancer Res 2003;1:863-70.
15. Sessa C. Cresta S, Cerny T, et al. Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors. Ann Oncol 2007;18: 561 -8.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000:92:205-16.
17. Supko J, Malspeis L A reversed-phase HPLC method for determining camptothecin in plasma with specificity for the intact lactone form of the drug. J Liquid Chromatogr 1991;14:1779-803.
18. Supko J, Malspeis L. Liquid chromatographic analysis of 9-aminocamptothecin in plasma monitored by fluorescence induced upon postcolumn acidification. J Liquid Chromatogr 1992:15:3261-83.
19. Supko JG, Malspeis L. Pharmacokinetics of the 9- amino and 10,11 -methylenedioxy derivatives of camptothecin in mice. Cancer Res 1993;53:3062-9.
20. Shah VP, Midha KK, Findlay JW, et al. Bioanalytical method validation-a revisit with a decade of progress. Pharm Res 2000:17:1551 -7.
21. Gabrielsson J, Weiner D. Pharmacokinetic/pharmacodynamic data analysis: concepts and applications. Stockholm (Sweden): Swedish Pharmaceutical Press; 1994.
22. Mizuta E, Tsubotani A. Preparation of mean drug concentration-time curves in plasma. A study on the frequency distribution of pharmacokinetic parameters. Chem Pharm Bull (Tokyo) 1985;33:1620-32.
23. Lacey LF, Keene ON, Pritchard JF, Bye A. Common noncompartmental pharmacokinetic variables: are they normally or log-normally distributed ? J Biopharm Stat 1997;7:171 -8.
24. Miller R.The jacknife-a review. Biometrika 1974;61: 1 -15.
25. Bom D, Curran DP, Kruszewski S, et al. The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamp- tothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J Med Chem 2000;43:3970-80.
26. BurkeTG, Mishra AK.Wani MC. Wall ME. Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry 1993;32:5352-64.
27. Mathijssen RH, van Alphen RJ.Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7:2182-94.
28. BurkeTG, Munshi CB, Mi Z, Jiang Y.The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. J Pharm Sci 1995;84:518-9.
29. Dallavalle S, Delsoldato T, Ferrari A, et al. Novel 7-substituted camptothecins with potent antitumor activity. J Med Chem 2000;43:3963-9.
30. Van Hattum AH, Pinedo HM, Schluper HM, Hausheer FH, Boven E. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. Int J Cancer 2000;88:260-6.
31. Daud A, Valkov N, Centeno B, et al. Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study. Clin Cancer Res 2005;11: 3009-16.
32. Thompson PA, Berg SL, Aleksic A, et al. Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates. Cancer Chemother Pharmacol 2004;53:527-32.
33. Mariani P, Moliterni A, Da Prada G, et al. A phase II trial of the novel oral camptothecin gimatecan (G) in women with anthracycline (A) and taxane (T) pre- treated advanced breast cancer. J Clin Oncol 2006 ASCO Annu Meet Proc Part I 2006:24:662.
34. Pecorelli S, Ray-Coquard I, Colombo N, et al. A phase II study of oral gimatecan (ST1481) in women with progressing or recurring advanced epithelial ovarian, fallopian tube and peritoneal cancers. J Clin Oncol 2006 ASCO Annu Meet Proc Part I 2006:24: 5088.
35. Thompson J, Stewart CF, Houghton PJ. Animal models for studying the action of topoisomerase I targeted drugs. Biochim Biophys Acta 1998:1400: 301 -19.